Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
17-beta-hydroxysteroid dehydrogenase type 3 (HSD17B3)
- Target
- HSD17B3
- Molecular classification
- Enzyme, Short-chain dehydrogenase/reductase family (SDR)
01
Overview
17-beta-hydroxysteroid dehydrogenase type 3 (HSD17B3) is a key enzyme predominantly expressed in testicular Leydig cells, catalyzing the final step in androgen biosynthesis—the conversion of androstenedione to testosterone. Mutations in the HSD17B3 gene cause impaired testosterone production, leading to disorders of sex development in genetic males, under-masculinization of external genitalia, and potential infertility. While alternative pathways and other isozymes can provide some compensation (notably in non-human species), HSD17B3 is the main enzyme for testicular testosterone synthesis in humans and plays a crucial role in male sexual differentiation and reproductive function.
- Other names
- 17β-Hydroxysteroid dehydrogenase 317β-HSD3HSD17B3EDH17B3SDR12C2Estradiol 17-beta-dehydrogenase 2Short chain dehydrogenase/reductase family 12C member 2Testicular 17-beta-hydroxysteroid dehydrogenaseTestosterone 17-beta-dehydrogenase 3Hydroxysteroid (17-beta) dehydrogenase 3
02
Mechanism of action
Inhibition of HSD17B3 reduces conversion of androstenedione to testosterone, leading to decreased androgen production.
03
Biological functions
Androgen biosynthesisSteroid metabolismConversion of androstenedione to testosterone
04
Disease associations
Disorders of sex development (DSD)Male pseudohermaphroditismInfertilityEndocrine disordersOther (potential link to hormone-related cancers, though not a primary cancer gene)
05
Safety considerations
Inhibition may cause undervirilization or ambiguous genitalia in malesPotential for altered estrogen/androgen balance leading to endocrine or reproductive abnormalities
06
Interacting drugs
There are no widely approved or classically used drugs directly targeting HSD17B3, but potential inhibitors are under preclinical investigation as part of androgen biosynthesis modulation for prostate cancer and other hormone-dependent conditions.
07
Biomarkers
Androstenedione/testosterone ratio (used diagnostically)HSD17B3 gene mutation/sequence analysis (used for diagnosis in DSD)
Beyond the preview
Go deeper on 17-beta-hydroxysteroid dehydrogenase type 3 (HSD17B3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 17-beta-hydroxysteroid dehydrogenase type 3 (HSD17B3).